Compare M&T Bank Corporation (MTB) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs Viatris Inc — how do they compare? M&T Bank Corporation trades at $217.69 (market cap $31.42B), while Viatris Inc trades at $17.7 (market cap $20.03B). The key difference: M&T Bank Corporation is the larger of the two by market cap, and M&T Bank Corporation pays the higher dividend (2.76%). Which is the better fit depends on your goals — on Pluang, investors hold M&T Bank Corporation for 100 Days and Viatris Inc for 57 Days on average.
| MTB | VTRS | |
|---|---|---|
Market Cap | $31.42B | $20.03B |
Volume | 1,438,219 | 14,109,977 |
Sector | Financials | Health |
52-Week High | $254.09 | $18.27 |
52-Week Low | $178.63 | $9.74 |
Typical Hold Time | 100 Days | 57 Days |
Enterprise Value | $47.77B | $32.15B |
Dividend Yield | 2.76% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
M&T Bank Corporation (MTB) trades at $217.23, up 0.29% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with P/E of 11.52, net margin of 30.85%, and consistent dividend payments. Recent news highlights branch expansion and AI investments driving loan growth, while analyst consensus remains cautiously optimistic with a $258.92 price target.
MTB presents a compelling value opportunity with attractive valuation metrics and solid profitability, though technical indicators suggest near-term pressure. The bank's strategic investments in technology and expanding fee businesses support long-term growth, but investors should monitor interest rate sensitivity and competitive banking sector dynamics.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
